Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1472-6963
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective ; volume:15 ; number:1 ; day:5 ; month:11 ; year:2015 ; pages:1-11 ; date:6.2015
BMC health services research ; 15, Heft 1 (5.11.2015), 1-11, 6.2015

Urheber
Charokopou, M.
Beteiligte Personen und Organisationen
McEwan, P.
Lister, S.
Callan, L.
Bergenheim, K.
Tolley, K.
Postema, R.
Townsend, R.
Roudaut, M.
SpringerLink (Online service)

DOI
10.1186/s12913-015-1139-y
URN
urn:nbn:de:1111-2016110520402
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:50 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Charokopou, M.
  • McEwan, P.
  • Lister, S.
  • Callan, L.
  • Bergenheim, K.
  • Tolley, K.
  • Postema, R.
  • Townsend, R.
  • Roudaut, M.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

Effectiveness of Dapagliflozin as Add-On to Metformin with or without Other Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Database Study

Effectiveness of Dapagliflozin as Add-On to Metformin with or without Other Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Database Study

Dapagliflozin/Metformin: Nutzenbewertung gemäß § 35a SGB V

Dapagliflozin/Metformin: Nutzenbewertung gemäß § 35a SGB V

Market Regulation of Voluntary Add-on Contracts

Konferenzbeitrag

Market Regulation of Voluntary Add-on Contracts

Shrouding add-on information: an experimental study

Konferenzbeitrag

Shrouding add-on information: an experimental study

Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes

Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes

Homöopathie - Add-on : komplementäre Empfehlungen zur konventionellen Medizin

Homöopathie - Add-on : komplementäre Empfehlungen zur konventionellen Medizin

Add-on Pricing, Consumer Myopia and Regulatory Intervention

Konferenzbeitrag

Add-on Pricing, Consumer Myopia and Regulatory Intervention

Auswahl und Integration einer anwendungsgerechten Add-on Hybridisierung

Hochschulschrift

Auswahl und Integration einer anwendungsgerechten Add-on Hybridisierung

Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study

Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study

Predictors of HbA1c treatment response to add-on medication following metformin monotherapy: a population-based cohort study

Predictors of HbA1c treatment response to add-on medication following metformin monotherapy: a population-based cohort study

Verbundene Objekte